Financial Statements — ALAR
Balance Sheet
(in millions USD)| Metric | Q2
2025 | Q2
2024 | Q2
2023 | Q2
2022 | Q2
2021 |
|---|
| Cash & Equivalents | 14.91 | 21.63 | 3.81 | 4.04 | 13.12 |
| Total Current Assets | 19.80 | 25.06 | 7.07 | 6.91 | 20.46 |
| Goodwill | 4.12 | 4.12 | 4.12 | 10.43 | 6.31 |
| Total Non-current Assets | 15.97 | 6.45 | 7.06 | 17.28 | 10.11 |
| Total Assets | 35.78 | 31.51 | 14.13 | 24.19 | 30.57 |
| Short-term Debt | -- | -- | -- | 0.40 | -- |
| Total Current Liabilities | 6.63 | 10.25 | 6.89 | 6.08 | 4.52 |
| Total Non-current Liabilities | 0.02 | 0.84 | 1.12 | 0.79 | 1.22 |
| Total Liabilities | 6.65 | 11.09 | 8.01 | 6.87 | 5.74 |
| Retained Earnings | (95.86) | (101.24) | (105.20) | (91.54) | (75.42) |
| Total Stockholder Equity | 29.13 | 20.42 | 6.12 | 17.32 | 24.83 |
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2
2025 | Q2
2024 | Q2
2023 | Q2
2022 | Q2
2021 |
|---|
| Total Revenue | 15.92 | 17.26 | 12.66 | 8.80 | 3.13 |
| Cost of Revenue* | 5.68 | 3.85 | 4.39 | 4.07 | 1.88 |
| Gross Profit | 10.24 | 13.41 | 8.27 | 4.73 | 1.25 |
| Research & Development | 3.16 | 2.14 | 1.95 | 2.28 | 1.48 |
| Selling, General & Admin | 2.87 | 2.63 | 2.29 | 4.25 | 0.22 |
| Total Operating Expenses | 9.93 | 8.14 | 17.02 | 12.76 | 6.07 |
| Operating Income | 0.31 | 5.27 | (8.74) | (8.03) | (4.82) |
| Pretax Income | 0.97 | 1.92 | 8.63 | 8.04 | 4.96 |
| Tax Provision | 0.28 | 0.83 | 0.24 | 0.15 | 0.08 |
| Net Income | 0.70 | 1.09 | (8.39) | (7.88) | (4.88) |
| Basic EPS | 0.01 | 0.02 | (0.25) | (0.26) | (0.20) |
| Diluted EPS | 0.01 | 0.02 | (0.25) | (0.26) | (0.20) |
* Derived from reported values
Cash Flow Statement
(in millions USD)| Metric | Q2
2025 | Q2
2024 | Q2
2023 | Q2
2022 | Q2
2021 |
|---|
| Operating Cash Flow | 0.21 | 6.28 | (0.14) | 4.95 | 3.43 |
| Investing Cash Flow | 0.12 | 0.21 | -- | 5.04 | (6.40) |
| Financing Cash Flow | (0.26) | 4.33 | 0.68 | 0.19 | 11.89 |
